A meta-analysis showed no significant differences between JAK inhibitor use and TNF antagonist use in terms of the risk for serious infections or malignant neoplasms in patients with immune-mediated ...
GlaxoSmithKline bought Sierra Oncology for momelotinib, a candidate that recently passed a phase III trial for a rare bone marrow cancer. Myelofibrosis affects around 20,000 people in the USA. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback